This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +24.08% per year. These returns cover a period from January 1, 1988 through May 6, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
pharmaceuticals: Archive
Bristol Myers (BMY) Reports Positive Data on Breyanzi, Opdivo (Revised)
by Zacks Equity Research
Bristol Myers (BMY) announces positive data from three studies evaluating CAR T cell therapy Breyanzi (liso-cel) and three updated analyses on studies evaluating Opdivo at ASCO.
BMYPositive Net Change NERVPositive Net Change KRYSPositive Net Change ALXONegative Net Change
biotechnology biotechs medical pharmaceuticals
Health Care Stocks Show Relative Strength as S&P 500 Stalls
by Bryan Hayes
Several stocks are breaking out and trading near all-time highs.
REGNNegative Net Change VRTXPositive Net Change
investing large-cap medical pharmaceuticals
Denali's (DNLI) Candidate Selected for FDA's START Pilot Program
by Zacks Equity Research
Denali's (DNLI) DNL126, an investigational enzyme replacement therapy, gets selected for the START Pilot Program, intended to accelerate the development of rare disease therapies.
SNYNegative Net Change BIIBPositive Net Change KRYSPositive Net Change DNLIPositive Net Change
biotechnology biotechs pharmaceuticals
Bristol Myers (BMY) Reports Positive Data on Breyanzi, Opdivo
by Zacks Equity Research
Bristol Myers (BMY) announces positive data from three studies evaluating CAR T cell therapy Breyanzi (liso-cel) and three updated analyses on studies evaluating Opdivo at ASCO.
BMYPositive Net Change NERVPositive Net Change KRYSPositive Net Change ALXONegative Net Change
biotechnology biotechs medical pharmaceuticals
TEVA Stock Rises 135% in a Year: What's Driving the Recovery?
by Zacks Equity Research
TEVA expects its newer drugs, Austedo, Uzedy and Ajovy, as well as a stable generics business, to help revive top-line growth in future quarters.
SNYNegative Net Change JNJPositive Net Change TEVAPositive Net Change ALVOPositive Net Change
pharmaceuticals
Top Analyst Reports for Roche, Wells Fargo & GE Aerospace
by Sheraz Mian
Today's Research Daily features new research reports on 16 major stocks, including Roche Holding AG (RHHBY), Wells Fargo & Company (WFC) and GE Aerospace (GE), as well as a micro-cap stock Key Tronic Corporation (KTCC).
WFCNegative Net Change GEPositive Net Change RHHBYNegative Net Change MCONegative Net Change DELLPositive Net Change EOGPositive Net Change KTCCNegative Net Change
finance pharmaceuticals transportation
FDA Panel to Consider Updating COVID-19 Jabs for New Virus Strains
by Sundeep Ganoria
An FDA panel meeting is scheduled on Jun 5 to consider if COVID-19 vaccines should be updated to target the WHO-recommended JN.1 variant or the KP.2 variant which is the currently dominating strain in the country.
PFENegative Net Change MRNANegative Net Change NVAXNegative Net Change
biotechs medical messenger-rna pharmaceuticals vaccines
Affimed (AFMD) Soars on Upbeat Follow-Up Data From NSCLC Study
by Zacks Equity Research
Affimed (AFMD) rallies 69% on positive follow-up efficacy data from its early to mid-stage study of the AFM24/Tecentriq combo therapy to treat heavily-pretreated EGFR wild-type NSCLC patients.
RHHBYNegative Net Change AFMDNegative Net Change ANVSPositive Net Change ALXONegative Net Change
biotechnology biotechs medical pharmaceuticals
Intellia (NTLA) Up on Upbeat Long-Term Angioedema Study Data
by Zacks Equity Research
Intellia (NTLA) gains 10% after reporting encouraging long-term efficacy data from the phase I portion of its early to mid-stage study evaluating NTLA-2002 for treating hereditary angioedema.
CGENNegative Net Change NTLAPositive Net Change ANVSPositive Net Change ALXONegative Net Change
biotechnology biotechs medical pharmaceuticals
Gilead (GILD), RCUS Announce Data From Colorectal Cancer Study
by Zacks Equity Research
Gilead (GILD) and partner Arcus Biosciences (RCUS) present data from metastatic colorectal cancer and gastrointestinal cancer study.
GILDPositive Net Change KRYSPositive Net Change RCUSPositive Net Change ALXONegative Net Change
biotechnology biotechs medical pharmaceuticals
AbbVie (ABBV) Skyrizi Gets CHMP Nod for Ulcerative Colitis in EU
by Zacks Equity Research
AbbVie (ABBV) announces that the EMA's CHMP issued a positive opinion on its regulatory filing seeking label expansion for the immunology drug, Skyrizi, to treat UC.
ABBVPositive Net Change ENTXPositive Net Change ANVSPositive Net Change ALXONegative Net Change
biotechnology biotechs medical pharmaceuticals
Moderna (MRNA) Secures FDA Nod for mRNA-Based RSV Vaccine
by Zacks Equity Research
The RSV vaccine is Moderna???s (MRNA) second FDA-approved product. Once the vaccine secures the CDC's recommendation, it will be launched in the 2024-2025 respiratory virus season.
GSKPositive Net Change PFENegative Net Change MRNANegative Net Change
biotechs medical messenger-rna pharmaceuticals vaccines
The Zacks Analyst Blog Highlights Eli Lilly, T-Mobile US, BHP, American International and Exelon
by Zacks Equity Research
Eli Lilly, T-Mobile US, BHP, American International and Exelon are part of the Zacks Analyst Blog.
EXCPositive Net Change LLYPositive Net Change BHPPositive Net Change AIGNo Net Change TMUSPositive Net Change
communications medical pharmaceuticals utilities
Top Research Reports for Eli Lilly, T-Mobile & BHP
by Sheraz Mian
Today's Research Daily features new research reports on 16 major stocks, including Eli Lilly and Company (LLY), T-Mobile US, Inc. (TMUS) and BHP Group Limited (BHP).
EXCPositive Net Change HPQNegative Net Change LLYPositive Net Change BHPPositive Net Change AIGNo Net Change TMUSPositive Net Change
communications industrial-products pharmaceuticals
Novartis (NVS) Reports Positive Long-Term Data on CSU Drug
by Zacks Equity Research
Novartis (NVS) reports phase III data that confirm sustained efficacy and long-term safety of oral remibrutinib in chronic spontaneous urticaria.
NVSPositive Net Change RHHBYNegative Net Change KRYSPositive Net Change ALXONegative Net Change
biotechnology biotechs medical pharmaceuticals
Gilead's (GILD) Urothelial Cancer Study Did Not Meet Its Primary Goal
by Zacks Equity Research
Gilead Sciences, Inc.'s (GILD) confirmatory TROPiCS-04 study on Trodelvy in locally advanced or metastatic urothelial cancer fails to achieve its primary endpoint.
GILDPositive Net Change ABBVPositive Net Change KRYSPositive Net Change ALXONegative Net Change
biotechnology biotechs medical pharmaceuticals
Ultragenyx (RARE) DTX401 Meets Goals in Metabolic Disorder Study
by Zacks Equity Research
Ultragenyx (RARE) reports meeting primary and secondary endpoints in the late-stage study of its investigational gene therapy, DTX401, to treat glycogen storage disease type Ia.
RAREPositive Net Change ENTXPositive Net Change ANVSPositive Net Change ALXONegative Net Change
biotechnology biotechs medical pharmaceuticals
FDA Delays Decision on Sanofi (SNY)-Regeneron Dupixent in COPD
by Zacks Equity Research
Per the FDA, the data submitted by Sanofi (SNY)/Regeneron (REGN) for Dupixent in COPD indication constitutes a major amendment to its previously-submitted data. A final decision is expected by Sep 27.
REGNNegative Net Change SNYNegative Net Change VRNAPositive Net Change
biotechs medical pharmaceuticals
Pharma Stock Roundup: JNJ, MRK M&A Deals, SNY, RHHBY Drugs' Priority Review & More
by Kinjel Shah
J&J (JNJ) and Merck (MRK) announce the acquisitions of private biotechs. The FDA grants Priority Review tags to Sanofi's (SNY) and Roche's (RHHBY) regulatory applications.
SNYNegative Net Change AZNPositive Net Change RHHBYNegative Net Change JNJPositive Net Change MRKPositive Net Change
pharmaceuticals
Merck (MRK) to Buy Private Ophthalmology Company EyeBio
by Zacks Equity Research
Merck's (MRK) acquisition of EyeBio is set to add the latter's lead pipeline candidate, Restoret, a novel Wnt agonist antibody being developed for treating retinal diseases.
JNJPositive Net Change MRKPositive Net Change HRTXPositive Net Change BVSPositive Net Change
pharmaceuticals
Immunovant (IMVT) Falls as Q4 Earnings Miss, Pipeline in Focus
by Zacks Equity Research
Immunovant (IMVT) declines 5% on dismal fourth-quarter fiscal 2024 results. The company names IMVT-1402 as its new lead candidate to initiate several studies for autoimmune indications.
BHVNPositive Net Change ENTXPositive Net Change IMVTPositive Net Change ALXONegative Net Change
biotechnology biotechs earnings medical pharmaceuticals
The Zacks Analyst Blog Highlights NVIDIA, Constellation Energy, Micron Technology, Moderna and Qualcomm
by Zacks Equity Research
NVIDIA, Constellation Energy, Micron Technology, Moderna and Qualcomm are part of the Zacks top Analyst Blog.
QCOMPositive Net Change CEGPositive Net Change MUPositive Net Change NVDAPositive Net Change MRNANegative Net Change
communications computers oil-energy pharmaceuticals semiconductor
Roche's (RHHBY) Inavolisib NDA Gets FDA Priority Review Tag
by Zacks Equity Research
The FDA grants priority review to Roche's (RHHBY) NDA for the inavolisib combination regimen for advanced hormone receptor-positive, HER2-negative breast cancer with a PIK3CA mutation.
AZNPositive Net Change RHHBYNegative Net Change PFENegative Net Change KRYSPositive Net Change
pharmaceuticals
AstraZeneca (AZN) Falls on Failure to Meet NSCLC Study OS Goal
by Zacks Equity Research
AstraZeneca's (AZN) shares decline as it fails to achieve statistically significant overall survival data in a late-stage NSCLC study on Dato-DXd compared with docetaxel.
AZNPositive Net Change ENTXPositive Net Change ANVSPositive Net Change ALXONegative Net Change
biotechnology biotechs medical oncology-screening pharmaceuticals
Prothena (PRTA), Bristol Myers Tie Up for Second Neuro Candidate
by Zacks Equity Research
Prothena (PRTA) announces that Bristol Myers is exercising its option for the second time, thereby in-licensing exclusive global rights for PRX019 to potentially treat neurodegenerative diseases.
BMYPositive Net Change PRTANegative Net Change ANVSPositive Net Change ALXONegative Net Change
biotechnology biotechs medical pharmaceuticals